DDInter898 DDInter150
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Meloxicam
Meloxicam {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvoxamine
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ganciclovir
Ganciclovir {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Nucleoside Analog {u} (Pharmacologic Class) includes {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ganciclovir
Ganciclovir {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) upregulates {v} (Gene) TPMT
TPMT {u} (Gene) is bound by {v} (Compound) Azathioprine
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Meloxicam and Meloxicam (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Azathioprine (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Azathioprine (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine (Compound) downregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Azathioprine (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Azathioprine (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Azathioprine (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Azathioprine (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) upregulates TPMT (Gene) and TPMT (Gene) is bound by Azathioprine (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Azathioprine (Compound)